Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 14, 2016; 22(2): 776-789
Published online Jan 14, 2016. doi: 10.3748/wjg.v22.i2.776
Published online Jan 14, 2016. doi: 10.3748/wjg.v22.i2.776
Targeted therapeutics | Ref. | Cell lines (cell type) | Main results |
Multikinase inhibitors | |||
Foretinib | Chen et al[32] | Panc-1(P) | Foretinib inhibited tumor growth, angiogenesis and lymphangiogenesis in xenograft animals, by inhibiting c-MET but VEGFR-2, VEGFR-3, and TIE-2 signaling |
SKLB261 | Pan et al[80] | BxPC-3 (P), | Application of SKLB261 resulted in more potent antitumor activities than dasatinib, gemcitabine, or erlotinib in pancreatic cancer xenografts |
Panc-1 (P), | |||
AsPC-1 (S), HPAC (P) | |||
Nintedanib | Awasthi et al[81] | AsPC-1 (S), | A triple angiokinase inhibitor, nintedanib inhibited growth of pancreatic cancer cell lines, with gemcitabine enhancing inhibitory effects |
BxPC-3 (P), | |||
Panc-1 (P), | |||
MIA-PaCa-2 (P), | |||
Dual inhibition | |||
Lapatinib and trametinib | Lindberg et al[101] | MAD 08-608, 08-738, 09-366 (P) | Dual anti-EGFR and anti-HER2 therapy significantly enhanced the growth inhibitory effects of the MEK1/2 inhibitor trametinib |
ZSTK474 and RO5126766 | Van Dort et al[99] | Panc-1 (P) | PI3K inhibitor and the Raf/MEK inhibitor RO5126766 resulted in high in vitro inhibition of both PI3Kand MEK1 also decreased cellular viability in pancreatic cancer cell line |
NVP-AEW541 and lapatinib | Urtasun et al[42] | NP-9, -18, -29 (P) | Combined treatment with the IGF-IR and EGFR/Her-2 inhibitors synergistically inhibited pancreatic cancer cell growth which is associated with abolishment of Akt, Efk, and IRS-1 activity |
CP15T, ,15A (p) | |||
Novel pathways | |||
PX-478 (HIF-a) | Zhao et al[84] | CFPAC-1 (S), BxPC-3 (P), | Combined treatment with gemcitabine/PX-478 significantly enhanced the anti-tumor effect which is associated with immunogenic cell death |
Panc-1 (P), | |||
MIA-PaCa-2 (P) | |||
SB216763(GSK-3b) | Marchand et al[86] | Panc-1 (P), | Inhibition of GSK-3βn induced apoptosis by mechanism involving JNK-cJUN activation |
MIA-PaCa-2 (P), BxPC-3 (P) | |||
Micro RNA | |||
miR-142-3p | MacKenzie et al[95] | MIA-PaCa-2 (P), Capan-1(S), | A unique HSP70 inhibiting compounds, miR-142-3p regulate triptolide-induced inhibition of pancreatic cancer growth |
HEK-293 (P), | |||
S2-013 (P) | |||
miR-146a | Li et al[96] | AsPC-1 (s), | miR-146a takes significant roles in pancreatic cancer invasion and metastasis but lower expressed in pancreatic cancer compared with normal pancreatic tissue |
Panc-1 (P) | |||
miR-494 | Li et al[97] | Colo357 (s), | miR-494, identified to affect levels of FOXM1 in pancreatic cancer cell lines and act as a negative regulator of this transcriptional activator, blocked nuclear translocation β-catenin |
Panc-1 (P) |
- Citation: Matsuoka T, Yashiro M. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol 2016; 22(2): 776-789
- URL: https://www.wjgnet.com/1007-9327/full/v22/i2/776.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i2.776